Johnson & Johnson shares jumped 1.2% in premarket trading on Tuesday after posting a strong first quarter. Both earnings and revenue beat analyst estimates, and the company slightly raised its full-year outlook. These results reinforce the stock’s position among 2026’s top large-cap performers, with shares up about 15% year-to-date, outperforming the nearly flat S&P 500.
Adjusted earnings for the first quarter were $2.70 per share, slightly above expectations. Sales reached $24.06 billion, about $450 million above analysts’ estimates and a 10% increase from last year. The Innovative Medicine segment led with over 11% sales growth, driven by the growing oncology portfolio. Meanwhile, the medical technology division grew by 7.7%, continuing its steady role as a secondary growth driver.
The company has raised its full-year outlook, now expecting sales of $100.3 to $101.3 billion and adjusted earnings of $11.45 to $11.65 per share. These modest increases reflect management’s measured confidence in demand, tempered by caution due to the uncertain economy.
Oncology is J&J’s top growth driver, anchored by three multiple myeloma drugs: Darzalex, Tecvayli, and Carvykti. Management targets $50 billion in cancer sales by 2030. Carvykti, a CAR-T cell therapy, achieved blockbuster status in 2025, boosting segment revenues. Although Darzalex faces patent expiry in the mid-2030s, J&J’s continued oncology innovation supports long-term growth.
Beyond oncology, J&J’s psychiatric drug portfolio is a growing focal point for analysts, especially with Caplyta, a recent acquisition through the purchase of Intra-Cellular Therapies and now approved as an add-on to antidepressants. While its blockbuster potential remains uncertain, Caplyta’s early gains broaden J&J’s earnings prospects in a market with little competition. Meanwhile, J&J’s valuation remains weighed down by talc litigation, with some 74,360 talc-related lawsuits still pending after a Texas bankruptcy court rejected the latest consolidation attempt. This ongoing legal uncertainty clouds an otherwise cleaner investment outlook, making litigation developments a key variable for traders assessing risk-adjusted returns. Despite this, J&J maintains its baby powder is safe and asbestos-free.
Featured CoursesRecent news
ServiceNow and Software Stocks Lead Sector Recovery on AI Hopes
Software stocks are making a comeback. ServiceNow jumped 8.8% on Monday, marking its largest one-day gain in over a year. This surge followed BofA Securities reinstating coverage with a Buy rating, which helped restore investor confidence in a sector that faced pressure in 2026 over concerns that AI might replace, not support, enterprise software. Here’s […]
GE Aerospace Stock Rises as AI Cuts Hypersonic Engine Design Time
GE Aerospace is showing investors what artificial intelligence looks like when applied to one of the world’s most technically demanding industries. Shares rose 1.58% Tuesday as the company revealed that researchers at its Niskayuna, New York, facility used an in-house generative AI tool to produce a preliminary hypersonic ramjet engine design, compressing a process that […]
Nvidia Shares Slip 1.1%: Why a 3-Day Losing Streak Could Be Good News
Nvidia is heading into its most anticipated earnings report of the year on the back foot, and that may be exactly what the stock needs. Shares fell 1.1% in premarket trading Tuesday, extending a three-day pullback from last Thursday’s closing high of $235.74. For investors watching closely, a lower entry point ahead of Wednesday’s results […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.